The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: A putative mechanism for the onset of Wernicke's encephalopathy

Drug Metabolism and Disposition

Volumn 42, Issue 10, 2014, Pages 1656-1662

  Zhang, Qiang ^a   Zhang, Yan ^a   Diamond, Sharon ^a   Boer, Jason ^a   Harris, Jennifer J ^a   Li, Yu ^a   Rupar, Mark ^a   Behshad, Elham ^a   Gardiner, Christine ^a   Collier, Paul ^a   Liu, Phillip ^a   Burn, Timothy ^a   Wynn, Richard ^a   Hollis, Gregory ^a   Yeleswaram, Swamy ^a  

^a Drug Metabolism Pharmacokinetics Clinical Pharmacology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FEDRATINIB; MESSENGER RNA; RUXOLITINIB; THIAMINE; TOFACITINIB; CARRIER PROTEIN; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; PHOSPHOTRANSFERASE; PROTEIN KINASE INHIBITOR; PYRROLIDINE DERIVATIVE; SLC19A3 PROTEIN, HUMAN; SULFONAMIDE; THIAMIN-DIPHOSPHATE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CACO 2 CELL LINE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG STRUCTURE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RAT; STEADY STATE; STRUCTURE ACTIVITY RELATION; THTR1 GENE; THTR2 GENE; TRANSCYTOSIS; VITAMIN METABOLISM; WERNICKE ENCEPHALOPATHY; ACTIVE TRANSPORT; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BRAIN; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLISM; THIAMINE DEFICIENCY;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; BRAIN; HUMANS; JANUS KINASE 2; MALE; MEMBRANE TRANSPORT PROTEINS; PHOSPHOTRANSFERASES (PHOSPHATE GROUP ACCEPTOR); PROTEIN KINASE INHIBITORS; PYRROLIDINES; RATS; SULFONAMIDES; THIAMINE; THIAMINE DEFICIENCY; WERNICKE ENCEPHALOPATHY;

EID: 84907912086     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.114.058883     Document Type: Article

References (22)

1. Ashokkumar B, Vaziri ND, and Said HM (2006) Thiamin uptake by the human-derived renal epithelial (HEK-293) cells: cellular and molecular mechanisms. Am J Physiol Renal Physiol 291:F796-F805.
2. Bukhari FJ, Moradi H, Gollapudi P, Ju Kim H, Vaziri ND, and Said HM (2011) Effect of chronic kidney disease on the expression of thiamin and folic acid transporters. Nephrol Dial Transplant 26:2137-2144.
3. Casirola D, Ferrari G, Gastaldi G, Patrini C, and Rindi G (1988) Transport of thiamine by brush-border membrane vesicles from rat small intestine. J Physiol 398:329-339.
4. Cook CC, Hallwood PM, and Thomson AD (1998) B Vitamin deficiency and neuropsychiatric syndromes in alcohol misuse. Alcohol Alcohol 33:317-336.
5. Dutta B, Huang W, Molero M, Kekuda R, Leibach FH, Devoe LD, Ganapathy V, and Prasad PD (1999) Cloning of the human thiamine transporter, a member of the folate transporter family. J Biol Chem 274:31925-31929.
6. Eudy JD, Spiegelstein O, Barber RC, Wlodarczyk BJ, Talbot J, and Finnell RH (2000) Identification and characterization of the human and mouse SLC19A3 gene: a novel member of the reduced folate family of micronutrient transporter genes. Mol Genet Metab 71: 581-590.
7. Greenwood J, Love ER, and Pratt OE (1982) Kinetics of thiamine transport across the blood-brain barrier in the rat. J Physiol 327:95-103.
8. Greenwood J and Pratt OE (1985) Comparison of the effects of some thiamine analogues upon thiamine transport across the blood-brain barrier of the rat. J Physiol 369:79-91.
9. Hopfer U, Nelson K, Perrotto J, and Isselbacher KJ (1973) Glucose transport in isolated brush border membrane from rat small intestine. J Biol Chem 248:25-32.
10. Izumi S, Nozaki Y, Komori T, Maeda K, Takenaka O, Kusano K, Yoshimura T, Kusuhara H, and Sugiyama Y (2013) Substrate-dependent inhibition of organic anion transporting polypeptide 1B1: comparative analysis with prototypical probe substrates estradiol-17b-glucuronide, estrone-3-sulfate, and sulfobromophthalein. Drug Metab Dispos 41:1859-1866.
11. Kalvass JC and Maurer TS (2002) Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23:327-338.
12. Larkin JR, Zhang F, Godfrey L, Molostvov G, Zehnder D, Rabbani N, and Thornalley PJ (2012) Glucose-induced down regulation of thiamine transporters in the kidney proximal tubular epithelium produces thiamine insufficiency in diabetes. PLoS ONE 7:e53175.
13. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, and Tefferi A (2011) Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 29:789-796.
14. Pardanani A, Harrison CN, Cortes JE, Cervantes F, Mesa RA, Milligan D, Masszi T, Mishchenko E, Jourdan E, and Vannucchi AM, et al. (2013) Results of a randomized, double-blind, placebo-controlled phase III study (JAKARTA) of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis (MF) (Abstract). Blood 122:393.
15. Reidling JC, Lambrecht N, Kassir M, and Said HM (2010) Impaired intestinal vitamin B1 (thiamin) uptake in thiamin transporter-2-deficient mice. Gastroenterology 138: 1802-1809.
16. Said HM, Balamurugan K, Subramanian VS, and Marchant JS (2004) Expression and functional contribution of hTHTR-2 in thiamin absorption in human intestine. Am J Physiol Gastrointest Liver Physiol 286:G491-G498.
17. Said HM, Ortiz A, Kumar CK, Chatterjee N, Dudeja PK, and Rubin S (1999) Transport of thiamine in human intestine: mechanism and regulation in intestinal epithelial cell model Caco-2. Am J Physiol 277:C645-C651.
18. Sanofi (Press release, November 18, 2013) Sanofi Discontinues Clinical Development of Investigational JAK2 Agent Fedratinib (SAR302503). Sanofi, Paris, France.
19. Subramanian VS, Nabokina SM, Lin-Moshier Y, Marchant JS, and Said HM (2013) Mitochondrial uptake of thiamin pyrophosphate: physiological and cell biological aspects. PLoS ONE 8:e73503.
20. Taub ME, Mease K, Sane RS, Watson CA, Chen L, Ellens H, Hirakawa B, Reyner EL, Jani M, and Lee CA (2011) Digoxin is not a substrate for organic anion-transporting polypeptide transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a substrate for a sodiumdependent transporter expressed in HEK293 cells. Drug Metab Dispos 39:2093-2102.
21. Yang Y, Faustino PJ, Volpe DA, Ellison CD, Lyon RC, and Yu LX (2007) Biopharmaceutics classification of selected beta-blockers: solubility and permeability class membership. Mol Pharm 4:608-614.
22. Yee S (1997) In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man - fact or myth. Pharm Res 14:763-766.